Focus:
Comment
-
23 May 2019
China drug in-licensing opportunities expected to swell as local pharma focus on R&D
Chinese drug companies are developing their own products, capitalising on unmet needs that the government is attempting to fill by approving Western drugs.
-
22 May 2019
Merck’s threat to Pfizer’s lucrative prevnar brand gains ground with positive Phase II results
The pediatric pneumococcal vaccine market is exceptionally lucrative, with PCV13 achieving global sales of $5.8 billion in 2018; therefore Pfizer stands to lose substantial income if Merck's V114 can garner...
-
22 May 2019
Pfizer acquires Therachon to broaden its rare disease pipeline
The acquisition will allow Pfizer to broaden its rare diseases portfolio by continuing the developing of TA-46, a potential first-in-class therapy that is currently in Phase I.
-
22 May 2019
US incident cases of Hepatitis A increase by 294% in 2016–2018 from 2013–2015
Hepatitis A is prominent in the US with a diagnosed incidence two to seven times as high as Western European markets and Japan.
-
21 May 2019
Cost-effectiveness could affect the uptake of Spravato for the treatment of MDD
Spravato is estimated to cost $198,000 per quality-adjusted life year (QALY) gained, exceeding the commonly cited cost-effectiveness thresholds of between $50,000–150,000 per QALY.
-
20 May 2019
Haemophilia pipeline reflects a shift towards alternative coagulation promoters
The development pipeline indicates that the promise of alternative coagulation promoters to target these areas of significant unmet need is becoming a reality.
-
20 May 2019
Novartis’ $305,800 approval price for Kymriah in Japan on par with high US price
CAR-T therapies are among the highest priced drugs in the pharmaceutical market, and the price set in Japan is close to the $373,000 price set in the US.
-
17 May 2019
Takeda takes a step forward in becoming dominant player in IBD landscape
The Japanese drugmaker intends to make Entyvio available in both a pre-filled syringe as well as a pen to add to its currently approved intravenous formulation.
-
17 May 2019
Skyrizi likely to uphold AbbVie’s position in the psoriasis market
GlobalData believes that Skyrizi’s strong results from the four Phase III trials demonstrate the drug can be a strong contender in the highly competitive psoriasis market.
-
16 May 2019
Disclosing list prices in TV adverts will not improve US drug pricing
While the intention behind the policy will certainly apply some pressure to Big Pharma, the introduction of list prices to TV ads has the potential to confuse consumers.